| Guardian Hospice Of Nashville, Llc 741 Cool Springs Boulevard, Suite 102, Franklin, TN, 37067 | |
| (615) 771-8979 |
News Archive
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago
| Name | Guardian Hospice Of Nashville, Llc |
|---|---|
| Location | 741 Cool Springs Boulevard, Suite 102, Franklin, Tennessee |
| Hospice ID | 441591 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 930 |
News Archive
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago
| NPI Number | 1770509051 |
| Organization Name | Guardian Hospice Of Nashville, Llc |
| Address | 741 Cool Springs Blvd Franklin, Tennessee, 37067 |
| Phone Number | (615)771-8979 |
News Archive
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 97.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 85.3 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 98.7 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 72.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.6 | 97.3 |
| Patients who got timely treatment for shortness of breath | 92.3 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 90.0 | 93.3 |
News Archive
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago
| Home Health Aides | 5 |
| Counselors | 2 |
| Homemakers | 5 |
| Licensed Practical or Vocational Nurses | 2 |
| Medical Social Workers | 2 |
| Physicians | 1 |
| Registered Nurses | 10 |
| Other Personnel | 4 |
| Total Employees | 31 |
|---|
News Archive
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago
| Willowbrook Hospice Inc Location: 1335 West Main Street Suite B, Franklin, Tennessee, 37064 Phone: (615) 771-8979 |
| Guardian Hospice Of Nashville, Llc Location: 741 Cool Springs Boulevard, Suite 102, Franklin, Tennessee, 37067 Phone: (615) 771-8979 |